Bioavailability of a new ketoprofen formulation for once-daily oral administration

International Journal of Pharmaceutics

Volumn 241, Issue 1, 2002, Pages 165-172

  Roda, A ^a   Sabatini, L ^a   Mirasoli, M ^a   Baraldini, M ^a   Roda, E ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Anti inflammatory drug; Bioavailability; Ketoprofen; Pharmacokinetics; Sustained release formulations

Indexed keywords

IBIFEN; KETOPROFEN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; FILM; HUMAN; KINETICS; MALE; NORMAL HUMAN; PH; PRIORITY JOURNAL; SUSTAINED RELEASE PREPARATION; TABLET;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; HUMANS; KETOPROFEN; MALE; SOLUBILITY;

EID: 0037043093     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(02)00230-2     Document Type: Article

References (20)

1. The effect of food on the systemic availability of ketoprofen
2. Bioavailability study on a new slow-release formulation of ketoprofen
3. Studies on 2-(3-benzoylphenyl) propionic acid ('Orudis')
4. Clinical evalutation of ketoprofen (19.583 R.P.) in rheumatoid arthritis-double-blind cross-over comparison with indomethacin
5. Aspects of the clinical pharmacology of non-steroidal anti-inflammatory drugs
6. Comparative pharmacokinetics of ketoprofen derived from single oral doses of ketoprofen capsules or a novel sustained-release pellet formulation
7. A pharmacokinetic study of repeated doses of a new controlled release form of ketoprofen
8. Ketoprofen (19.583 R.P.) (2-(3-benzoyl-phenyl)-propionic acid). Main pharmacological properties: Outline of toxicological and pharmacokinetic data
9. Effect of diet on the single- and multiple-dose pharmacokinetics of sustained-release ketoprofen
10. Ketoprofen
11. A double-blind, interpatient comparison of plain and slow-release ketoprofen in osteoarthritis
12. A comparative trial of a controlled-release formulation of ketoprofen ('Oruvail') and a conventional capsule formulation of ketoprofen ('Orudis') in patients with osteoarthritis of the hip
13. Circadian changes in the pharmacokinetics of oral ketoprofen
14. High-performance liquid chromatographic determination of ketoprofen and naproxen in rat plasma
15. Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets
16. Ketoprofen pharmacokinetics and bioavailability based on an improved sensitive and specific assay
17. Release of vasoactive substances from guinea-pig lungs by slow-reacting substance C and arachidonic acid. Its blockade by nonsteroid anti-inflammatory agents
18. An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen